MYC/BCL2 double-hit lymphoma in a patient with rheumatoid arthritis associated with methotrexate treatment

2Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Several reports have suggested an increased risk of malignant lymphoma in patients with rheumatoid arthritis treated with methotrexate (MTX). We herein describe the case of a 71-year-old woman with rheumatoid arthritis who developed MYC/BCL2 double-hit lymphoma associated with MTX therapy. She developed a fever and lymphadenopathies over a 2-week period and had elevated levels of soluble IL-2 receptor. Inguinal lymph node and bone marrow biopsies showed diffuse large B cell lymphoma. Fluorescent in situ hybridization revealed MYC and BCL2 gene rearrangements in her lymphoma cells. Accordingly, a diagnosis of MYC/ BCL2 double-hit lymphoma was made. This is the first reported case of a double-hit lymphoma associated with MTX therapy.

Cite

CITATION STYLE

APA

Kurimoto, R., Shono, K., Onoda, M., Yamamoto, K., & Yokota, A. (2016). MYC/BCL2 double-hit lymphoma in a patient with rheumatoid arthritis associated with methotrexate treatment. Internal Medicine, 55(16), 2271–2275. https://doi.org/10.2169/internalmedicine.55.6156

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free